CAS-Ruiyi

CAS-Ruiyi (中科睿医) is a Beijing-based medtech company developing quantitative assessment systems for neurological function, combining intelligent human-computer interaction technology from the Chinese Academy of Sciences with clinical expertise from top-tier hospitals including Peking Union Medical College Hospital and Beijing Tiantan Hospital . Founded in 2021, the company established a joint neuroscience innovation center with Peking Union Medical College Hospital that same year , and has since organized multi-center clinical trials with over a dozen leading Chinese neurosurgery hospitals to build normative data models for motor and cognitive function in Chinese populations .

The company has raised multiple rounds from institutional investors: BlueRun Ventures led its Pre-A round in 2022 , HETANG Venture Capital led its Series A in early 2023 , and China Reform Fund led a Series A+ round in late 2024 , with ZhenFund also participating as an angel investor . Its more recent work includes launching a multi-center research initiative on multidimensional brain aging assessment with 18 medical institutions including Beijing Tiantan Hospital .